SCYX Stock Analysis: Buy, Sell, or Hold?
SCYX - SCYNEXIS, Inc.
$4.48
0.10 (2.28%)
▲
5d:
-5.29%
30d:
+7.95%
90d:
+348.0%
HOLD
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 12, 2026
28d
Get Alerted When SCYX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SCYX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SCYX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: SCYX is currently trading at $4.48, which is considered slightly high relative to its 30-day fair value range of $3.91 to $4.52. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.8) compared to its historical average (1.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SCYX is in a uptrend. Immediate support is located at $0.68, while resistance sits at $5.62.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.55 (+648.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SCYX is in a uptrend. Immediate support is located at $0.68, while resistance sits at $5.62.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $33.55 (+648.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.91 -
$4.52
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 648.8% below Wall St target ($33.55)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -5.3% 5-day decline
Trading Range Analysis
30-Day Trading Range
$3.91 -
$4.52
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.80
(17.9%)
Support & Resistance Levels
Support Level
$0.68
Resistance Level
$5.62
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.78
Wall Street Target
$33.55
(+648.8%)
Revenue Growth (YoY)
1808.5%
Profit Margin
-120.5%
PE vs Historical
-1.8 vs 1.5
CHEAP
Share & Embed Analysis
Last updated: July 14, 2026 2:48 AM ET
Data refreshes hourly during market hours. Next update: 3:48 AM
Data refreshes hourly during market hours. Next update: 3:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCYX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
